Cargando…
Amelioration of Hepatic Steatosis by the Androgen Receptor Inhibitor EPI-001 in Mice and Human Hepatic Cells Is Associated with the Inhibition of CYP2E1
Nonalcoholic fatty liver disease (NAFLD) is recognized as a metabolic disease characterized by hepatic steatosis. Despite the growing burden of NAFLD, approved pharmacological treatment is lacking. As an inhibitor of androgen receptor (AR), EPI-001 is being explored for the treatment of prostate can...
Autores principales: | Wang, Shuqin, Li, Xue, Xu, Weizhe, Gao, Jing, Wang, Yin, Jia, Xiaoyuan, Li, Gongchu, Pan, Qiuwei, Chen, Kan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785868/ https://www.ncbi.nlm.nih.gov/pubmed/36555703 http://dx.doi.org/10.3390/ijms232416063 |
Ejemplares similares
-
Betaine in ameliorating alcohol-induced hepatic steatosis
por: Rehman, Aisha, et al.
Publicado: (2021) -
Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI‐001 in in vitro Models of Prostate Cancer Drug Resistance
por: Nicolescu, Radu Costin Bizga, et al.
Publicado: (2022) -
Quercitrin Ameliorates Hyperlipidemia and Hepatic Steatosis in Ovariectomized Mice
por: Hur, Haeng Jeon, et al.
Publicado: (2020) -
Dietary Leucine Supplement Ameliorates Hepatic Steatosis and Diabetic Nephropathy in db/db Mice
por: Chen, Kuan-Hsing, et al.
Publicado: (2018) -
Inhibition of DHCR24 activates LXRα to ameliorate hepatic steatosis and inflammation
por: Zhou, Enchen, et al.
Publicado: (2023)